Oculis (NASDAQ:OCS) Sees Strong Trading Volume Following Analyst Upgrade

Oculis Holding AG (NASDAQ:OCS) shares saw unusually-high trading volume on Friday after Robert W. Baird raised their price target on the stock from $37.00 to $41.00. Robert W. Baird currently has an outperform rating on the stock. Approximately 37,965 shares were traded during trading, a decline of 16% from the previous session’s volume of 45,132 shares.The stock last traded at $18.53 and had previously closed at $18.70.

Other research analysts have also recently issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Oculis in a report on Thursday. HC Wainwright cut their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday.

Institutional Investors Weigh In On Oculis

A number of hedge funds and other institutional investors have recently modified their holdings of OCS. Bellevue Group AG acquired a new stake in shares of Oculis in the 4th quarter valued at $170,000. XTX Topco Ltd acquired a new stake in Oculis during the 4th quarter worth $225,000. Geode Capital Management LLC raised its stake in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after acquiring an additional 1,800 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Oculis during the 4th quarter worth $389,000. Finally, Bank of America Corp DE grew its position in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The company’s 50-day simple moving average is $20.92 and its 200-day simple moving average is $16.97. The company has a market capitalization of $760.26 million, a PE ratio of -9.73 and a beta of 0.02.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, sell-side analysts anticipate that Oculis Holding AG will post -2.09 earnings per share for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.